Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - PROLUNG INCFinancial_Report.xls
EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATIONS - PROLUNG INCf10qa063012_ex31z2.htm
EX-32.2 - EXHIBIT 32.2 SECTION 906 CERTIFICATIONS - PROLUNG INCf10qa063012_ex32z2.htm
EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATIONS - PROLUNG INCf10qa063012_ex31z1.htm
EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATIONS - PROLUNG INCf10qa063012_ex32z1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549


Form 10-Q/A

Amendment No. 1


  X . QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended June 30, 2012


      . TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Commission file number:  000-54600


FRESH MEDICAL LABORATORIES, INC.

(Exact name of registrant as specified in its charter)


Delaware

  

20-1922768

(State or other jurisdiction of incorporation or organization)

  

(I.R.S. Employer Identification No.)


757 East South Temple, Suite 150

  

  

Salt Lake City, Utah

  

84102

(Address of principal executive offices)

  

(Zip Code)


(801) 736–0729

(Registrant’s telephone number, including area code)


Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   

Yes      . No   X  .


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   

Yes   X  . No      .


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Ruble 12b-2 of the Exchange Act.


Large accelerated filer

      .

Accelerated filer

      .

Non-accelerated filer

      . (Do not check if a smaller reporting company)

Smaller reporting company

  X .


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      . No   X  .


The number of shares of Common Stock, $0.001 par value, outstanding on August 9, 2012 was 10,434,718.






FRESH MEDICAL LABORATORIES, INC.


Explanatory Note


This Amendment No. 1 on Form 10-Q/A amends the registrant’s Quarterly Report on Form 10-Q  for the quarterly period ending June 30,  2012  as filed with the Securities and Exchange Commission by the registrant on August 17, 2012. This Amendment is filed to include the 101 XBRL Interactive Data File exhibits required by Item 6.  No other items are being amended except as described in this Explanatory Note and this Amendment does not reflect any events occurring after the filing of the original Quarterly Report on Form 10-Q for the period ending June 30, 2012.





PART II – OTHER INFORMATION


ITEM 6.  EXHIBITS.


 

 

Exhibit

Number

Description

31.1

Certification of Chief Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*

XBRL (eXtensible Business Reporting Language)


*XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.






SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


FRESH MEDICAL LABORATORIES, INC.

                     (Registrant)


By: /s/ Steven C. Eror                                

Steven C. Eror

Chief Executive Officer, President, and Director

(Principal Executive Officer)

 

Date: September 7, 2012



By: /s/ Steven C. Eror                               

Steven C. Eror

Acting Chief Financial Officer

(Acting Principal Financial and Accounting Officer)


Date: September 7, 2012